References
- Braganza S, Sharif I, Ozuah PO. Documenting asthma severity: do we get it right? J Asthma. 2003 Sep;40(6):661-5.
- Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol. 2003 Sep;112(3):469-78; quiz 479.
- Ververeli K, Chipps B. Oral corticosteroid: sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma. Ann Allergy Asthma Immunol 2004; 5: 512-522
- Orsini L, Limpa-Amara S, Crown WH, Stanford RH, Kamal K,Asthma hospitalization risk and cost for patients treated with fluticasone propionate vs Montelukast. Ann Allergy, Asthma, Immunol 2004; 5: 523-9
- Van der Molen T, Foster J. IPCRG 2004
- Nimi A et al, Effect of Short-term treatment with inhaled corticosteroid on airway wall thickening in asthma. Ann J Med 2004; 116(11): 775-777
- Jones C, Santanello NC, Boccuzzi SJ, Wogen J, Strub P, Nelsen LM. Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data. J Asthma. 2003 Feb;40(1):93-101.
- Asthma Management: Perspectives and Paradigms in a Changing Environment Conference Report. Chairs Anthony S Rebuck, Paul M O'Byrne. CHEST. Vol. 111, No. 2, February 1997 Supplement
American College of Chest Physicians
- Plavec D. ARIA – one airway, one disease: what links our research to the concept? Arh Hig Rada Toksikol. 2004 Jun;55(2-3):135-40.
- British Guideline on the Management of Asthma British Thoracic Society and Scottish Intercollegiate Guidelines Network. Revised edition July 2007. (Click here)
Previous references
|
